Major Advantages of Dako's HER2 IQFISH pharmDx™ in Breast Cancer Diagnostics
News Feb 18, 2014
The Toulouse, France, breast cancer group led by Magali Lacroix-Triki, has published a peer-reviewed publication in the Journal of Histopathology that supports the use and performance of Dako's HER2 IQFISH pharmDx™ for HER2 gene amplification status assessment in breast cancer. Dako introduced the cutting-edge IQFISH hybridization buffer chemistry in 2012. The IQFISH buffer reduces test turnaround time from 17 hours to just 3.5 hours.
More than 1.5 million new cases of breast cancer are diagnosed each year worldwide. As an aid in the treatment decision, HER2 IQFISH pharmDx™ can quantitatively determine HER2 gene amplification in the tumor.
The French study found that Instant Quality (IQ) FISH provides "excellent quality signals without any background staining, thus allowing excellent reading conditions(1)." The study also points out "almost perfect agreement between IQFISH and FISH" and that IQFISH is a "safe, reliable and fast method that is easy to use in routine practice" with few reruns. The statement is significant in that the tissue came from five different laboratories using four different fixation methods.
The study concludes that the highly concordant results (99.3%) and assay robustness support IQFISH as a useful alternative to FISH, allowing reliable assessment of HER2 status. It also finds that using this method enables pathologists to report the results to the oncologist within a day, meaning patients can begin cancer treatment sooner than ever.
The study's findings follow those of another study showing major advantages of using Dako's IQFISH chemistry. A Hungarian study, published in 2013 in the Journal of Applied Immunohistochemistry and Molecular Morphology(3), showed several advantages of the new hybridization buffer:
"The one-day HER2 IQFISH approach is a potent method for the determination of HER2 status offering some relevant advances further to the short incubation time, including enhanced tissue integrity and preserved fluorescent signal intensity when compared with the conventional HER2 FISH kit." Hegyi et al., 2013.
"At Dako, we are focused on the advancement of cancer diagnostics, so we are particularly proud of these findings regarding our IQFISH buffer," said Britt Meelby Jensen, Dako general manager and vice president. "We understand that the speed and accuracy of patient sample processing and the quality of test performance affect the treatment decisions and outcome for patients."
An additional benefit of the IQFISH buffer is that it avoids the use of toxic formamide in assays and eliminates concerns for pregnant laboratory technicians. The buffer is environmentally friendly and does not require a fume hood during use.
Comments | 0 ADD COMMENT
Tempus, UPenn Team Up to Improve Leukemia Treatment
News Apr 28, 2017